Perspectives on Cost and Value in Cancer Care

Jerry Avorn, The $2.6 Billion Pill — Methodologic and Policy Considerations New England Journal of Medicine. ,vol. 372, pp. 1877- 1879 ,(2015) , 10.1056/NEJMP1500848

Feriyl Bhaijee, Thomas Huebner, Ralph H. Hruban, Laura D. Wood, Nathan Cuka, Drew M. Pardoll, Nickolas Papadopoulos, Kenneth W. Kinzler, Shibin Zhou, Toby C. Cornish, Janis M. Taube, Robert A. Anders, James R. Eshleman, Bert Vogelstein, Luis A. Diaz, Dung T. Le, Jennifer N. Uram, Hao Wang, Bjarne R. Bartlett, Holly Kemberling, Aleksandra D. Eyring, Andrew D. Skora, Brandon S. Luber, Nilofer S. Azad, Dan Laheru, Barbara Biedrzycki, Ross C. Donehower, Atif Zaheer, George A. Fisher, Todd S. Crocenzi, James J. Lee, Steven M. Duffy, Richard M. Goldberg, Albert de la Chapelle, Minori Koshiji, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency The New England Journal of Medicine. ,vol. 372, pp. 2509- 2520 ,(2015) , 10.1056/NEJMOA1500596

Edward B Garon, Naiyer A Rizvi, Rina Hui, Natasha Leighl, Ani S Balmanoukian, Joseph Paul Eder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn, Enric Carcereny, Myung-Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew D Hellmann, Omid Hamid, Jonathan W Goldman, Jean-Charles Soria, Marisa Dolled-Filhart, Ruth Z Rutledge, Jin Zhang, Jared K Lunceford, Reshma Rangwala, Gregory M Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi, None, Pembrolizumab for the treatment of non-small cell lung cancer The New England Journal of Medicine. ,vol. 372, pp. 2018- 2028 ,(2015) , 10.1056/NEJMOA1501824

Sham Mailankody, Vinay Prasad, Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs JAMA Oncology. ,vol. 1, pp. 539- 540 ,(2015) , 10.1001/JAMAONCOL.2015.0373

N.I. Cherny, R. Sullivan, U. Dafni, J.M. Kerst, A. Sobrero, C. Zielinski, E.G.E. de Vries, M.J. Piccart, A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) Annals of Oncology. ,vol. 26, pp. 1547- 1573 ,(2015) , 10.1093/ANNONC/MDV249

David H. Howard, Peter B. Bach, Ernst R. Berndt, Rena M. Conti, Pricing in the Market for Anticancer Drugs Journal of Economic Perspectives. ,vol. 29, pp. 139- 162 ,(2015) , 10.1257/JEP.29.1.139

Caroline Robert, Jacob Schachter, Georgina V. Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Omid Hamid, Christine Mateus, Ronnie Shapira-Frommer, Michele Kosh, Honghong Zhou, Nageatte Ibrahim, Scot Ebbinghaus, Antoni Ribas, Pembrolizumab versus Ipilimumab in Advanced Melanoma The New England Journal of Medicine. ,vol. 372, pp. 2521- 2532 ,(2015) , 10.1056/NEJMOA1503093

R. A. Young, J. E. DeVoe, Who Will Have Health Insurance in the Future? An Updated Projection Annals of Family Medicine. ,vol. 10, pp. 156- 162 ,(2012) , 10.1370/AFM.1348

Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal, Cancer statistics, 2015. CA: A Cancer Journal for Clinicians. ,vol. 65, pp. 5- 29 ,(2015) , 10.3322/CAAC.21254

Jedd D. Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, Piotr Rutkowski, Jean Jacques Grob, Charles Lance Cowey, Christopher D. Lao, Dirk Schadendorf, Pier Francesco Ferrucci, Michael Smylie, Reinhard Dummer, Andrew Graham Hill, John B. A. G. Haanen, Michele Maio, Grant A. McArthur, Arvin Yang, Linda Rollin, Christine E. Horak, James M. G. Larkin, F. Stephen Hodi, Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). Journal of Clinical Oncology. ,vol. 33, ,(2015) , 10.1200/JCO.2015.33.18_SUPPL.LBA1